MedTrace Logo

Real wOrld studY in the Adjuvant Setting for High Risk earLy Breast Cancer Patients

NCT07151911 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2025-09-03

No results posted yet for this study

Summary

The primary goal of this observational study is to describe the distribution of treatment options and patients' characteristics according to the definition of high-risk status in the early breast cancer (EBC) setting. Participants already taking intervention as part of their regular medical care for EBC will answer questionnaires to also assess quality of life and patient reported outcomes.

The recruitment phase will last about 2 years, each patient will be followed up for 5 years.

Conditions

Interventions

DRUG

abemaciclib, olaparib and endocrine therapy

Patients receiving abemaciclib, olaparib and endocrine therapy.

Sponsors & Collaborators

  • Azienda Ospedaliero-Universitaria di Modena

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-08-26
Primary Completion
2026-09-30
Completion
2031-09-30

Countries

  • Italy

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07151911 on ClinicalTrials.gov